Moderna, Inc. - Common Stock (NQ:MRNA)

190.01 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

99 100 Next >

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 06, 2025

Via Benzinga

Which S&P500 stocks are gapping on Tuesday? ↗

May 06, 2025

Wondering which stocks are making significant price gaps? Explore the S&P500 index on Tuesday to find the gap up and gap down stocks in today's session.

Via Chartmill

Vertex Pharmaceuticals Topples 12% On A Series Of First-Quarter Setbacks ↗

May 06, 2025

The company paused a study of a cystic fibrosis treatment, right on the heels of a scrapped type 1 diabetes program.

Via Investor's Business Daily

Topics Government Intellectual Property

3 Cash-Heavy Stocks in the Doghouse

May 05, 2025

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits,...

Via StockStory

Topics Economy

Earnings Scheduled For May 1, 2025 ↗

May 01, 2025

Via Benzinga

Preview: Moderna's Earnings ↗

April 30, 2025

Via Benzinga

What's going on in today's session: S&P500 movers ↗

May 01, 2025

Stay updated with the movements of the S&P500 index in the middle of the day on Thursday. Discover which stocks are leading as top gainers and losers in today's session.

Via Chartmill

Moderna Expands Cost-Cutting Program By Up To $1.7 Billion, FDA Approval For Flu/COVID-19 Combo Shot Delayed Into 2026 ↗

May 01, 2025

Moderna reaffirms 2025 revenue guidance of $1.5 billion–$2.5 billion, cuts 2027 cost forecast by up to $1.7 billion, and targets 2026 approval for its flu/COVID combo shot.

Via Benzinga

Thursday's session: gap up and gap down stock in the S&P500 index ↗

May 01, 2025

Curious about the S&P500 stocks that are gapping on Thursday? Explore the gap up and gap down stocks in the S&P500 index during today's session.

Via Chartmill

Moderna Reports Q1 Revenue Drop, Warns Of Delay In Covid/Flu Vaccine Approval: Retail Sentiment Sours ↗

May 01, 2025

The company reported first-quarter revenue of $108 million, down from $167 million in the corresponding period of 2024, and below an analyst estimate of $115.32 million, as per FinChat data.

Via Stocktwits

These S&P500 stocks are moving in today's pre-market session ↗

May 01, 2025

Get insights into the top gainers and losers in the S&P500 index of Thursday's pre-market session.

Via Chartmill

Moderna (NASDAQ:MRNA) Misses Q1 Revenue Estimates

May 01, 2025

Biotechnology company Moderna (NASDAQ:MRNA) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 35.3% year on year to $108 million. The company’s full-year revenue guidance of $2...

Via StockStory

Moderna Misses Sales Forecasts, But Maintains Full-Year Outlook ↗

May 01, 2025

The company is well known for its Covid vaccine. But sales came in below expectations.

Via Investor's Business Daily

Topics Earnings Government

Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates

May 01, 2025

Via ACCESS Newswire

Moderna (MRNA) Reports Earnings Tomorrow: What To Expect

April 30, 2025

Biotechnology company Moderna (NASDAQ:MRNA) will be announcing earnings results tomorrow before market hours. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence World Trade

Trump-Era FDA Appointees Request New Trials For Novavax COVID Vaccine, Reportedly Delaying Approval Timeline ↗

April 29, 2025

The President Donald Trump administration's request for Novavax Inc. to conduct new clinical trials for its COVID-19 vaccine has created uncertainty across the vaccine industry, potentially affecting...

Via Benzinga

Topics Government

Down 36%, Is Moderna a Buy on the Dip? ↗

April 28, 2025

Via The Motley Fool

Market Sell-Off: 2 Stocks Down 17% and 36% This Year to Buy and Hold ↗

April 26, 2025

Via The Motley Fool

10 Worst Performing Large-Caps Last 12 Months ↗

April 24, 2025

Here’s this week’s top 10 worst performing Large-Caps in the last twelve months.

Via Talk Markets

Topics Stocks / Equities

3 Healthcare Stocks Facing Headwinds

April 24, 2025

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of...

Via StockStory

Topics Stocks

These S&P500 stocks are moving in today's session ↗

April 21, 2025

Stay informed about the performance of the S&P500 index one hour before the close of the markets on Monday. Uncover the top gainers and losers in today's session for valuable insights.

Via Chartmill

Discover which S&P500 stocks are making waves on Monday. ↗

April 21, 2025

Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Monday.

Via Chartmill

Wall Street Sinks, Dollar Slides As Trump Ramps Up Fed Attacks: What's Driving Markets Monday? ↗

April 21, 2025

Stocks in the U.S. were trading sharply lower by midday Monday, while gold and Bitcoin (CRYPTO: BTC) surged in tandem, as a renewed political storm surrounding Federal Reserve independence shook...

Via Benzinga

Topics Economy Government

Where Will Moderna Be in 5 Years? ↗

April 20, 2025

Via The Motley Fool

5 Stocks to Buy the Dip, According to AI ↗

April 20, 2025

“Buy the dip” strategies are hard to get right, but they can yield phenomenal results. Now, TradeSmith believes they’ve found a way to help longer-term investors find attractive entry points into great...

Via InvestorPlace

Topics Artificial Intelligence

10 Worst Performing Large-Caps Last 12 Months ↗

April 19, 2025

Here’s this week’s top 10 worst performing Large-Caps in the last twelve months.

Via Talk Markets

Topics Stocks / Equities

US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years ↗

April 17, 2025

CDC panel expands Pfizer and GSK RSV vaccine use to high-risk adults 50–59, building on earlier recommendations for older populations.

Via Benzinga

Bloom Energy, Rogers, 3D Systems, Moderna, and EchoStar Stocks Trade Down, What You Need To Know

April 16, 2025

A number of stocks fell in the afternoon session after Federal Reserve Chair Jerome Powell signaled a cautious stance on future monetary policy decisions during a speech in Chicago, emphasizing that...

Via StockStory

Topics Economy Government World Trade

Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks

April 16, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with AbbVie...

Via StockStory

Topics Artificial Intelligence

Uncover the latest developments among S&P500 stocks in today's session. ↗

April 15, 2025

Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday.

Via Chartmill

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.